JP2014515751A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515751A5
JP2014515751A5 JP2014505470A JP2014505470A JP2014515751A5 JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5 JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014505470 A JP2014505470 A JP 2014505470A JP 2014515751 A5 JP2014515751 A5 JP 2014515751A5
Authority
JP
Japan
Prior art keywords
seq
grf analog
ala
grf
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515751A (ja
JP6113144B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/050242 external-priority patent/WO2012142706A1/en
Publication of JP2014515751A publication Critical patent/JP2014515751A/ja
Publication of JP2014515751A5 publication Critical patent/JP2014515751A5/ja
Application granted granted Critical
Publication of JP6113144B2 publication Critical patent/JP6113144B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505470A 2011-04-21 2012-04-17 成長ホルモン放出因子(grf)類似体およびその使用 Expired - Fee Related JP6113144B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477775P 2011-04-21 2011-04-21
US61/477,775 2011-04-21
PCT/CA2012/050242 WO2012142706A1 (en) 2011-04-21 2012-04-17 Growth hormone releasing factor (grf) analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2014515751A JP2014515751A (ja) 2014-07-03
JP2014515751A5 true JP2014515751A5 (enExample) 2015-06-11
JP6113144B2 JP6113144B2 (ja) 2017-04-12

Family

ID=47021786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505470A Expired - Fee Related JP6113144B2 (ja) 2011-04-21 2012-04-17 成長ホルモン放出因子(grf)類似体およびその使用

Country Status (10)

Country Link
US (1) US8361964B2 (enExample)
EP (1) EP2699591A4 (enExample)
JP (1) JP6113144B2 (enExample)
KR (1) KR20140027284A (enExample)
CN (1) CN103547591A (enExample)
AR (1) AR087727A1 (enExample)
BR (1) BR112013027150A2 (enExample)
CA (1) CA2833434A1 (enExample)
MX (1) MX2013012259A (enExample)
WO (1) WO2012142706A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2017181277A1 (en) * 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4617149A (en) 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4801456A (en) 1987-07-09 1989-01-31 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
EP0307860B1 (en) * 1987-09-18 1994-06-08 F. Hoffmann-La Roche Ag Cyclic GRF-analogs
NZ237857A (en) * 1990-04-24 1992-05-26 Lilly Co Eli Polypeptide compounds with growth hormone releasing factor activity
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
EP0820296A4 (en) 1995-04-14 1999-06-30 Univ Tulane ANALOGS OF THE GROWTH HORMONE-RELEASING FACTOR
BRPI9608799B8 (pt) 1995-05-26 2019-11-05 Theratechnologies Inc análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
BR0206919A (pt) * 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
BR0210915A (pt) * 2001-06-08 2004-06-08 Sod Conseils Rech Applic Análogos quiméricos de somatostatina-dopamina
KR20050071498A (ko) 2002-09-18 2005-07-07 상트르 오스피딸리에 드 루니버시떼 드 몬트리알 성장 호르몬 방출 호르몬 유사체
WO2004105789A1 (en) 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
CA2542433A1 (en) 2003-10-20 2005-04-28 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
KR101228229B1 (ko) 2004-10-20 2013-01-31 쎄러테크놀로지스 인코포레이티드 성장 호르몬 분비 촉진물질 및 그의 용도
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20100267636A1 (en) 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy

Similar Documents

Publication Publication Date Title
JP2013515057A5 (enExample)
IL262805B1 (en) CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death
JP2013515055A5 (enExample)
TWI374030B (en) Use of melanocortins to treat insulin sensitivity
JP2014521684A5 (enExample)
JP2011526886A5 (enExample)
FI3482765T3 (fi) Pitkävaikutteinen kasvuhormoni ja menetelmiä sen tuottamiseksi
JP2013522311A5 (enExample)
BR122020011001B1 (pt) Peptídeo derivados de oxintomodulina e seu uso, polinucleotídeo, composição farmacêutica e seu uso e método para prevenção ou tratamento da obesidade compreendendo os mesmos
JP2011511753A5 (enExample)
JP2005524648A5 (enExample)
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP2013518057A5 (enExample)
JP2007509984A5 (enExample)
JP2013517307A5 (enExample)
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
JP2004504406A5 (enExample)
JP2014050390A5 (enExample)
JP2008530245A5 (enExample)
JP2010529957A5 (enExample)
JP2009191078A5 (enExample)
JP2019533722A5 (enExample)
JP2013501802A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2011518179A5 (enExample)